Zoledronate disodium

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 463607

CAS#: 131654-46-1 (disodium)

Description: Zoledronate disodium is an inhibitor of osteoclastogenesis and macrophage recruitment, decreasing bone turnover and stabilizing the bone matrix, exhibiting diverse anti-tumor effects in osteosarcoma.


Chemical Structure

img
Zoledronate disodium
CAS# 131654-46-1 (disodium)

Theoretical Analysis

MedKoo Cat#: 463607
Name: Zoledronate disodium
CAS#: 131654-46-1 (disodium)
Chemical Formula: C5H8N2Na2O7P2
Exact Mass:
Molecular Weight: 316.0531
Elemental Analysis: C, 19.00; H, 2.55; N, 8.86; Na, 14.55; O, 35.43; P, 19.60

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Related CAS #: 118072-93-8 (free acid)   165800-06-6 (free acid hydrate)   131654-46-1 (disodium)   827573-11-5 (trisodium)   165800-07-7 (disodium hydrate)   165800-08-8 (trisodium hydrate)    

Synonym: Zoledronate disodium; CGP-42446A; CGP42446A; CGP 42446A;

IUPAC/Chemical Name: sodium (1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl)bis(hydrogen phosphonate)

InChi Key: OPQQEYHAVUNQNA-UHFFFAOYSA-L

InChi Code: InChI=1S/C5H10N2O7P2.2Na/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7;;/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14);;/q;2*+1/p-2

SMILES Code: O=P(C(P([O-])(O)=O)(O)CN1C=CN=C1)(O)[O-].[Na+].[Na+]

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 316.0531 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Ralston SH. Bisphosphonates in the management of Paget's disease. Bone. 2020 Sep;138:115465. doi: 10.1016/j.bone.2020.115465. Epub 2020 Jun 5. PMID: 32512166.

2: Li P, Hu Y. "Turn-Off" Fluorescent Sensor for Pamidronate Disodium and Zoledronic Acid Based on Newly Synthesized Carbon Dots from Black Tea. J Anal Methods Chem. 2018 Mar 13;2018:3631249. doi: 10.1155/2018/3631249. PMID: 29725552; PMCID: PMC5872615.

3: Ong MWS, Jones L. Improving Bisphosphonate Infusion Monitoring at Haematology Medical Day Unit. BMJ Qual Improv Rep. 2017 Mar 31;6(1):u206586.w4692. doi: 10.1136/bmjquality.u206586.w4692. PMID: 28469896; PMCID: PMC5388016.

4: Hortobagyi GN, Van Poznak C, Harker WG, Gradishar WJ, Chew H, Dakhil SR, Haley BB, Sauter N, Mohanlal R, Zheng M, Lipton A. Continued Treatment Effect of Zoledronic Acid Dosing Every 12 vs 4 Weeks in Women With Breast Cancer Metastatic to Bone: The OPTIMIZE-2 Randomized Clinical Trial. JAMA Oncol. 2017 Jul 1;3(7):906-912. doi: 10.1001/jamaoncol.2016.6316. PMID: 28125763; PMCID: PMC5824238.

5: Yang L, Du S. Efficacy and Safety of Zoledronic Acid and Pamidronate Disodium in the Treatment of Malignant Skeletal Metastasis: A Meta-Analysis. Medicine (Baltimore). 2015 Oct;94(42):e1822. doi: 10.1097/MD.0000000000001822. PMID: 26496320; PMCID: PMC4620752.

6: Seal B, Sullivan SD, Ramsey SD, Asche CV, Shermock K, Sarma S, Zagadailov EA, Farrelly E, Eaddy M. Comparing hospital-based resource utilization and costs for prostate cancer patients with and without bone metastases. Appl Health Econ Health Policy. 2014 Oct;12(5):547-57. doi: 10.1007/s40258-014-0101-1. PMID: 25005491; PMCID: PMC4175039.

7: Biernacka J, Betlejewska-Kielak K, Kłosińska-Szmurło E, Pluciński FA, Mazurek AP. Prediction of bioavailability of selected bisphosphonates using in silico methods towards categorization into a biopharmaceutical classification system. Acta Pol Pharm. 2013 Sep-Oct;70(5):877-82. PMID: 24147367.

8: De Ponte FS, Favaloro A, Siniscalchi EN, Centofanti A, Runci M, Cutroneo G, Catalfamo L. Sarcoglycans and integrins in bisphosphonate treatment: immunohistochemical and scanning electron microscopy study. Oncol Rep. 2013 Dec;30(6):2639-46. doi: 10.3892/or.2013.2766. Epub 2013 Oct 1. PMID: 24100935.

9: Faiman B, Pillai AL, Benghiac AG. Bisphosphonate-related osteonecrosis of the jaw: historical, ethical, and legal issues associated with prescribing. J Adv Pract Oncol. 2013 Jan;4(1):25-35. PMID: 25031978; PMCID: PMC4093372.

10: Henk HJ, Kaura S. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan. J Med Econ. 2012;15(1):175-84. doi: 10.3111/13696998.2011.632044. Epub 2011 Nov 8. PMID: 22017235.

11: Vuorimies I, Toiviainen-Salo S, Hero M, Mäkitie O. Zoledronic acid treatment in children with osteogenesis imperfecta. Horm Res Paediatr. 2011;75(5):346-53. doi: 10.1159/000323368. Epub 2011 Feb 2. PMID: 21293106.

12: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Jun;32(5):331-88. doi: 10.1358/mf.2010.32.5.1520420. PMID: 20664824.

13: Treeprasertsuk S, Silveira MG, Petz JL, Lindor KD. Parenteral bisphosphonates for osteoporosis in patients with primary biliary cirrhosis. Am J Ther. 2011 Sep;18(5):375-81. doi: 10.1097/MJT.0b013e3181d7e1d3. PMID: 20460985.

14: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2010 Apr;32(3):193-215. doi: 10.1358/mf.2010.32.3.1492017. PMID: 20448862.

15: Tomillero A, Moral MA. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2009 Apr;31(3):183-226. PMID: 19536362.

16: Moral MA, Tomillero A. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Mar;30(2):149-71. PMID: 18560631.

17: Bayés M, Rabasseda X. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2008 Jan-Feb;30(1):67-99. PMID: 18389098.

18: Brown JJ, Ramalingam L, Zacharin MR. Bisphosphonate-associated osteonecrosis of the jaw: does it occur in children? Clin Endocrinol (Oxf). 2008 Jun;68(6):863-7. doi: 10.1111/j.1365-2265.2008.03189.x. Epub 2008 Jan 21. PMID: 18221397.

19: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Dec;29(10):697-735. PMID: 18200333.

20: Heras Rincón I, Zubillaga Rodríguez I, Castrillo Tambay M, Montalvo Moreno JJ. Osteonecrosis of the jaws and bisphosphonates. Report of fifteen cases. Therapeutic recommendations. Med Oral Patol Oral Cir Bucal. 2007 Aug 1;12(4):E267-71. PMID: 17664910.